Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved symbols : Bgne save search
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.93%
H: 3.2%
C: 2.66%
fda brukinsa approval treatment
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
Published: 2023-12-22 (Crawled : 13:30) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.24%
H: 2.84%
C: 0.69%
brukinsa fda label update leukemia
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-11-17 (Crawled : 16:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.0%
H: 0.38%
C: -1.21%
brukinsa approval treatment
FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Published: 2023-06-21 (Crawled : 14:20) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.8%
H: 0.36%
C: -2.33%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.18%
H: 0.8%
C: -0.5%
blincyto fda approval treat grants leukemia
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
Published: 2023-05-30 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.15%
H: 1.79%
C: -3.79%
brukinsa approved treatment canada leukemia
FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 7.48%
H: 0.45%
C: -4.8%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.32%
H: 0.2%
C: -1.16%
rituxan fda biosimilar
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
Published: 2022-04-15 (Crawled : 11:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
china cell carcinoma
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
Published: 2022-03-11 (Crawled : 20:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.43%
H: 0.0%
C: 0.0%
satellite rosa solid tumors air china ism
HUTCHMED Receives Approval to Commercialize ELUNATE® in MacauFirst homegrown innovative medicine approved in Macau based on China clinical data
Published: 2022-03-01 (Crawled : 11:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: 0.0%
elunate approval china commercialization
HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau
Published: 2022-03-01 (Crawled : 09:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 1.17%
H: 4.14%
C: 2.64%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: 0.0%
elunate approval commercialization
LUMAKRAS® (sotorasib) Receives Approval In Japan For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2022-01-20 (Crawled : 11:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.95%
H: 2.8%
C: 1.37%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.07%
lumakras approval cel lung cancer cancer
EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Published: 2022-01-10 (Crawled : 06:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.38%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 2.3%
H: 0.0%
C: 0.0%
cancer
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
Published: 2021-12-03 (Crawled : 08:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.98%
H: 0.0%
C: 0.0%
ema approval disease china injection
FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse
Published: 2021-12-01 (Crawled : 19:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.03%
H: 1.18%
C: 0.22%
fda
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
Published: 2021-09-15 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.2%
H: 1.82%
C: -0.44%
fda brukinsa approval granted grant
Health Canada approves LUMAKRAS™ (sotorasib), the first and only targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
Published: 2021-09-14 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.0%
H: 1.86%
C: 1.28%
treatment lung cancer cancer
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
Published: 2021-08-17 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -2.33%
H: 4.04%
C: 2.74%
risk china approval pharma
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
Published: 2021-07-26 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -3.99%
H: 2.19%
C: -10.03%
treatment brukinsa approval
BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
Published: 2021-07-09 (Crawled : 09:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.63%
H: 3.3%
C: 2.21%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.49%
H: 1.17%
C: 0.87%
china injection approval
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
Published: 2021-06-23 (Crawled : 10:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.74%
H: 2.99%
C: 2.16%
lung cancer china cancer approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
MGOL 4 | $0.229 -4.18% 13.72% 420K
|
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
Your saved searches
Save your searches and get alerts when important news are released.